MedTrace Logo

Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741

NCT01068028 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2010-08-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of ORM-12741.

Conditions

  • Healthy

Interventions

DRUG

ORM-12741

Ascending multiple doses to sequential panels

DRUG

Placebo for ORM-12741

Sponsors & Collaborators

  • Orion Corporation, Orion Pharma

    lead INDUSTRY

Principal Investigators

  • Déborah Metzger, MD · Forenap Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-06-30
Completion
2010-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01068028 on ClinicalTrials.gov